Angiotensin receptor 1 blocker valsartan normalizes gene expression profiles of 3T3-L1 adipocytes altered by co-culture with LPS-treated RAW264.7 macrophages.

[1]  I. Komuro,et al.  Valsartan, independently of AT1 receptor or PPARγ, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. , 2012, American journal of physiology. Endocrinology and metabolism.

[2]  T. Asano,et al.  Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: Potential link with metabolic complications , 2012, Innate immunity.

[3]  Y. Matsuki,et al.  Overexpression of KLF15 Transcription Factor in Adipocytes of Mice Results in Down-regulation of SCD1 Protein Expression in Adipocytes and Consequent Enhancement of Glucose-induced Insulin Secretion* , 2011, The Journal of Biological Chemistry.

[4]  J. Després,et al.  Adiposity and pulmonary function: relationship with body fat distribution and systemic inflammation. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.

[5]  P. Iglesias,et al.  Prevalence of Thyroid Dysfunction in Patients with Type 2 Diabetes , 2011, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[6]  S. Ghosh,et al.  NF-κB, inflammation, and metabolic disease. , 2011, Cell metabolism.

[7]  D. Górecka,et al.  Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects , 2010, European journal of medical research.

[8]  T. Suganami,et al.  Adipose tissue macrophages: their role in adipose tissue remodeling , 2010, Journal of leukocyte biology.

[9]  O. Okosieme,et al.  Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies , 2010, International journal of clinical practice.

[10]  Ursula A White,et al.  Transcriptional factors that promote formation of white adipose tissue , 2010, Molecular and Cellular Endocrinology.

[11]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[12]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[13]  P. Schauer,et al.  Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis* , 2009, The Journal of Biological Chemistry.

[14]  Christina K. Chan,et al.  Differential Effect of Saturated and Unsaturated Free Fatty Acids on the Generation of Monocyte Adhesion and Chemotactic Factors by Adipocytes , 2009, Diabetes.

[15]  H. Matsubara,et al.  Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. , 2009, European heart journal.

[16]  D. Mazzatti,et al.  Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage-conditioned medium , 2009, Pflügers Archiv - European Journal of Physiology.

[17]  D. Fitchett.  Results of the ONTARGET and TRANSCEND studies: an update and discussion , 2008, Vascular health and risk management.

[18]  S. Aydin,et al.  The relationship of inflammatory cytokines with asthma and obesity. , 2008, Clinical and investigative medicine. Medecine clinique et experimentale.

[19]  T. Asano,et al.  DNA microarray analyses of genes expressed differentially in 3T3-L1 adipocytes co-cultured with murine macrophage cell line RAW264.7 in the presence of the toll-like receptor 4 ligand bacterial endotoxin , 2008, International Journal of Obesity.

[20]  C. Glass,et al.  A Subpopulation of Macrophages Infiltrates Hypertrophic Adipose Tissue and Is Activated by Free Fatty Acids via Toll-like Receptors 2 and 4 and JNK-dependent Pathways* , 2007, Journal of Biological Chemistry.

[21]  S. Takashiba,et al.  Macrophage‐Adipocyte Interaction: Marked Interleukin‐6 Production by Lipopolysaccharide , 2007, Obesity.

[22]  G. Davis,et al.  The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus , 2007, Diabetes, obesity & metabolism.

[23]  R. Kitazawa,et al.  MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. , 2006, The Journal of clinical investigation.

[24]  T. Suganami,et al.  A Paracrine Loop Between Adipocytes and Macrophages Aggravates Inflammatory Changes: Role of Free Fatty Acids and Tumor Necrosis Factor α , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[25]  A. Quyyumi,et al.  Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome , 2004, Circulation.

[26]  E. Bruckert,et al.  Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women , 2004, International Journal of Obesity.

[27]  Mitchell A. Avery,et al.  Identification of Telmisartan as a Unique Angiotensin II: Receptor Antagonist With Selective PPARγ–Modulating Activity , 2004, Hypertension.

[28]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[29]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[30]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[31]  Y. Watanabe,et al.  Constitutively active mitogen-activated protein kinase kinase increases GLUT1 expression and recruits both GLUT1 and GLUT4 at the cell surface in 3T3-L1 adipocytes. , 2000, Diabetes.

[32]  U. Smith,et al.  Culprit Underlying the Metabolic Syndrome and Atherosclerosis , 2007 .

[33]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.